Capricorn Therapeutics shares rose 26.5% after the earnings call, as investors responded to the company’s account of positive HOPE-3 efficacy data and its view that the FDA review is nearing completion. The BLA remains under review, with the agency’s target action date extended to November 22.
Capricor Therapeutics reported significant advancements ahead of the anticipated results from the pivotal HOPE-3 Phase 3 study of Daramycin, targeting Duchenne muscular dystrophy, bolstered by a robust safety profile demonstrated across a significant patient population.